Health Catalyst (NASDAQ:HCAT – Get Rating) had its price target dropped by equities researchers at Piper Sandler from $38.00 to $21.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Piper Sandler’s price target points to a potential upside of 62.16% from the stock’s previous close.
A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of Health Catalyst from $62.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, March 2nd. Jefferies Financial Group raised shares of Health Catalyst from a “hold” rating to a “buy” rating and decreased their target price for the company from $31.00 to $28.00 in a research note on Thursday, March 17th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $66.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. BTIG Research cut their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, March 25th. Finally, SVB Leerink cut their price target on shares of Health Catalyst from $64.00 to $48.00 and set an “outperform” rating on the stock in a report on Wednesday, March 2nd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of “Buy” and an average price target of $36.23.
HCAT stock opened at $12.95 on Wednesday. Health Catalyst has a 1 year low of $12.53 and a 1 year high of $59.50. The firm has a 50-day moving average of $22.49 and a 200 day moving average of $32.50. The company has a market cap of $698.48 million, a P/E ratio of -4.03 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.46 and a quick ratio of 5.46.
In related news, COO Paul Horstmeier sold 23,209 shares of the firm’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $25.30, for a total value of $587,187.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Daniel H. Orenstein sold 4,112 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total transaction of $110,283.84. The disclosure for this sale can be found here. Insiders sold 37,286 shares of company stock worth $934,979 in the last 90 days. 2.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Fairfield Bush & CO. purchased a new position in shares of Health Catalyst during the 1st quarter worth $25,000. UMB Bank N A MO purchased a new position in shares of Health Catalyst during the 4th quarter worth $30,000. Manchester Capital Management LLC boosted its stake in shares of Health Catalyst by 667.5% during the 1st quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock worth $30,000 after acquiring an additional 1,008 shares during the last quarter. Sageworth Trust Co of South Dakota purchased a new position in shares of Health Catalyst during the 4th quarter worth $61,000. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Health Catalyst by 27.3% during the 3rd quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after acquiring an additional 314 shares during the last quarter. Institutional investors and hedge funds own 97.53% of the company’s stock.
About Health Catalyst (Get Rating)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.